Although the recent clinical trial targeting LOXL2 inhibition (ClinicalTrials.gov NCT01769196) was halted early because of a lack of efficacy (Raghu et al., 2017), the present study suggests that targeting LOXL1 in IPF might be as important as targeting LOXL2. The gene discussed is LOXL1; the disease is idiopathic pulmonary fibrosis.